190 related articles for article (PubMed ID: 28426920)
1. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment.
Bonello L; Laine M; Camoin-Jau L; Frere C
J Thromb Haemost; 2017 Jul; 15(7):1522-1523. PubMed ID: 28426920
[No Abstract] [Full Text] [Related]
2. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: reply.
Achilles A; Mohring A; Zeus T; Kelm M; Polzin A
J Thromb Haemost; 2017 Jul; 15(7):1524-1525. PubMed ID: 28445598
[No Abstract] [Full Text] [Related]
3. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
Achilles A; Mohring A; Dannenberg L; Grandoch M; Hohlfeld T; Fischer JW; Levkau B; Kelm M; Zeus T; Polzin A
J Thromb Haemost; 2017 Mar; 15(3):473-476. PubMed ID: 27992120
[TBL] [Abstract][Full Text] [Related]
4. Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran.
Nehaj F; Sokol J; Mokan M; Ivankova J; Mokan M
Clin Appl Thromb Hemost; 2018 Mar; 24(2):268-272. PubMed ID: 28703014
[TBL] [Abstract][Full Text] [Related]
5. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Olivier CB; Weik P; Meyer M; Weber S; Anto-Michel N; Diehl P; Zhou Q; Geisen U; Bode C; Moser M
Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy.
Sokol J; Nehaj F; Ivankova J; Mokan M; Mokan M; Stasko J
Scand Cardiovasc J; 2018 Aug; 52(4):227-231. PubMed ID: 29842807
[TBL] [Abstract][Full Text] [Related]
7. Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran.
Oi K; Shimizu M; Natori T; Tsuda K; Yoshida M; Kamada A; Ishigaku Y; Narumi S; Oura K; Maeda T; Terayama Y
Thromb Res; 2021 May; 201():123-130. PubMed ID: 33667955
[TBL] [Abstract][Full Text] [Related]
8. The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbα-Mediated Platelet Aggregation.
Trabold K; Makhoul S; Gambaryan S; van Ryn J; Walter U; Jurk K
Thromb Haemost; 2019 Jun; 119(6):916-929. PubMed ID: 31005062
[TBL] [Abstract][Full Text] [Related]
9. Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation.
Tsuda K; Natori T; Shimizu M; Ishigaku Y; Oi K; Narumi S; Kamada A; Yoshida M; Oura K; Maeda T; Terayama Y
Thromb Res; 2020 May; 189():1-4. PubMed ID: 32120029
[No Abstract] [Full Text] [Related]
10. Enhanced TRAP-induced platelet aggregation with dabigatran - Clinical perspective.
Bhagirath VC; Bosch J; Eikelboom JW
Thromb Res; 2016 Feb; 138():61-62. PubMed ID: 26757599
[No Abstract] [Full Text] [Related]
11. Impact of dabigatran on platelet function and fibrinolysis.
Tsantes AE; Kyriakou E; Bonovas S; Chondrogianni M; Zompola C; Liantinioti C; Simitsi A; Katsanos AH; Atta M; Ikonomidis I; Kapsimali V; Kopterides P; Tsivgoulis G
J Neurol Sci; 2015 Oct; 357(1-2):204-8. PubMed ID: 26219486
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran-related platelet thrombin response during triple anti-thrombotic therapy: A matter of time?
Witkowski M; Steffens D; Hassanein A; Witkowski M; Kränkel N; Doerner A; Friebel J; Landmesser U; Rauch U
Thromb Res; 2017 Jan; 149():62-63. PubMed ID: 27907813
[No Abstract] [Full Text] [Related]
14. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG
Solbeck S; Jensen AS; Maschmann C; Stensballe J; Ostrowski SR; Johansson PI
Scand J Clin Lab Invest; 2018; 78(1-2):25-30. PubMed ID: 29304563
[TBL] [Abstract][Full Text] [Related]
15. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
[TBL] [Abstract][Full Text] [Related]
16. Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration - results from a diabetes animal model.
Scridon A; Mărginean A; Huțanu A; Chinezu L; Gheban D; Perian M; Vântu A; Gherțescu D; Fișcă PC; Șerban RC; Chevalier P; Dobreanu D
J Thromb Haemost; 2019 Mar; 17(3):538-550. PubMed ID: 30653813
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
Nakazaki M; Oka S; Magota H; Kiyose R; Onodera R; Ukai R; Kataoka-Sasaki Y; Sasaki M; Honmou O
J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106520. PubMed ID: 35523052
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation.
Watanabe T; Shinoda Y; Ikeoka K; Minamisaka T; Fukuoka H; Inui H; Hoshida S
Intern Med; 2017; 56(15):1977-1980. PubMed ID: 28768967
[TBL] [Abstract][Full Text] [Related]
19. [New anticoagulants - direct thrombin inhibitors].
Brand B; Graf L
Ther Umsch; 2012 Nov; 69(11):643-9. PubMed ID: 23117667
[TBL] [Abstract][Full Text] [Related]
20. [Modern Approaches to Prevention of Thromboembolic Complications in Patients With Nonvalvular Atrial Fibrillation With a Direct Thrombin Inhibitor Dabigatran].
Savina NM
Kardiologiia; 2016 Jul; 56(7):91-99. PubMed ID: 28290913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
